Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Phase 1

Recruiting

Conditions: Hepatic Impairment (HI)

Interventions: Drug: Nemtabrutinib

First Posted Date: 2024-06-04

Last Posted Date: 2025-03-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT06442436

Locations: 🇺🇸
Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
🇺🇸
Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: IV Tulisokibart
Drug: SC Tulisokibart
Other: IV Placebo
Other: SC Placebo

First Posted Date: 2024-05-28

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06430801

Locations: 🇭🇰
Queen Mary Hospital ( Site 3300), Hksar, Hong Kong
🇺🇸
GI Alliance - Southlake ( Site 5109), Southlake, Texas, United States
🇯🇵
Okayama University Hospital ( Site 3454), Okayama, Japan

and more 380 locations

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Belzutifan
Drug: Everolimus
Drug: Fulvestrant
Drug: Exemestane

First Posted Date: 2024-05-24

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT06428396

Locations: 🇨🇴
IMAT S.A.S ( Site 1205), Monteria, Cordoba, Colombia
🇨🇦
Jewish General Hospital ( Site 0400), Montreal, Quebec, Canada
🇬🇧
Ipswich Hospital ( Site 1911), Ipswich, Suffolk, United Kingdom

and more 29 locations

Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)

Phase 3

Recruiting

Conditions: Systolic Dysfunction

Interventions: Drug: Vericiguat tablet
Drug: Vericiguat suspension

First Posted Date: 2024-05-24

Last Posted Date: 2025-02-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 342

Registration Number: NCT06428383

Locations: 🇺🇸
Le Bonheur Children's Hospital ( Site 0007), Memphis, Tennessee, United States
🇨🇴
Clinica Somer-Unidad de Investigacion y Docencia ( Site 0607), Rionegro, Antioquia, Colombia
🇮🇪
Children's Health Ireland (CHI) at Crumlin ( Site 1400), Dublin, Ireland

and more 4 locations

A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Phase 1

Recruiting

Conditions: Colorectal Cancer
Biliary Tract Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Biological: Sacituzumab tirumotecan
Drug: Fluorouracil (5-FU)
Drug: Leucovorin (LV) or levoleucovorin
Drug: Rescue medication
Drug: Supportive care measures

First Posted Date: 2024-05-24

Last Posted Date: 2025-06-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT06428409

Locations: 🇺🇸
UCLA ( Site 0317), Los Angeles, California, United States
🇺🇸
University of Colorado Anschutz Medical Campus ( Site 0299), Aurora, Colorado, United States
🇺🇸
UCHealth Cherry Creek Medical Center ( Site 0326), Denver, Colorado, United States

and more 52 locations

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer
NSCLC

Interventions: Biological: Pembrolizumab
Biological: sac-TMT
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2024-05-20

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 851

Registration Number: NCT06422143

Locations: 🇧🇷
Oncoclínica Oncologistas Associados ( Site 0309), Terezina, Piaui, Brazil
🇺🇸
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122), Burbank, California, United States
🇺🇸
Exempla Lutheran Medical Center ( Site 0119), Golden, Colorado, United States

and more 176 locations

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Phase 1

Recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia
Diffuse Large B-cell Lymphoma
Burkitt Lymphoma
Neuroblastoma
Ewing Sarcoma

Interventions: Biological: Zilovertamab vedotin

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 90

Registration Number: NCT06395103

Locations: 🇺🇸
Children's Hospital Los Angeles ( Site 1006), Los Angeles, California, United States
🇺🇸
Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado, United States
🇺🇸
Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut, United States

and more 50 locations

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Phase 1

Withdrawn

Conditions: Neoplasm Metastasis

Interventions: Biological: Pembrolizumab
Biological: Pembrolizumab/Vibostolimab
Biological: Favezelimab/Pembrolizumab
Biological: Favezelimab
Biological: Vibostolimab

First Posted Date: 2024-05-01

Last Posted Date: 2025-04-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 80

Registration Number: NCT06395090

Locations: 🇺🇸
Yale-New Haven Hospital ( Site 2012), New Haven, Connecticut, United States
🇺🇸
University of Iowa-Holden Comprehensive Cancer Center ( Site 2017), Iowa City, Iowa, United States
🇺🇸
Children's Mercy Hospital ( Site 2024), Kansas City, Missouri, United States

and more 9 locations

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3

Recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Biological: Pembrolizumab
Biological: Sacituzumab tirumotecan
Drug: Capecitabine

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1530

Registration Number: NCT06393374

Locations: 🇺🇸
Holy Cross Hospital ( Site 0069), Silver Spring, Maryland, United States
🇺🇸
Hightower Clinical, LLC ( Site 0085), Oklahoma City, Oklahoma, United States
🇺🇸
Texas Oncology - Northeast Texas ( Site 8005), Flower Mound, Texas, United States

and more 216 locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Phase 3

Recruiting

Conditions: Gastroesophageal Cancer

Interventions: Drug: Trifluridine-Tipiracil
Biological: Sacituzumab tirumotecan
Drug: Irinotecan
Drug: Rescue medication
Drug: Supportive care measures
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2024-04-10

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 450

Registration Number: NCT06356311

Locations: 🇨🇳
Hubei Cancer Hospital ( Site 3012), Wuhan, Hubei, China
🇮🇱
Rabin Medical Center ( Site 1605), Petah Tikva, Israel
🇮🇱
Sourasky Medical Center ( Site 1602), Tel Aviv, Israel

and more 163 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy